search
Back to results

Examining the Effects of Neuromodulation on Glucose Metabolism in Type 2 Diabetes

Primary Purpose

Type 2 Diabetes

Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
TNM (thermoneuromodulation device)
Sponsored by
Scion NeuroStim
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Type 2 Diabetes focused on measuring neuromodulation, caloric vestibular stimulation, Type 2 Diabetes

Eligibility Criteria

18 Years - 70 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria

A subject is eligible for the study if all of the following criteria are met:

  • Provide written informed consent prior to enrollment.
  • Is male or female between 18-70 years old.
  • Has been diagnosed with type II diabetes for greater than 12 months.
  • Is currently either using lifestyle modification or taking one or two of the following oral antihyperglycemic agents and has been on stable doses for 90 days prior to screening:

    • metformin
    • DPP-4 inhibitors (sitagliptin, saxagliptin, alogliptin, linaglyptin)
    • Pioglitazone
    • GLP-1 agonist (exenatide, liraglutide, exenatide LAR)
    • SGLT-2 Inhibitors (dapaglifozin, canagliflozin)
  • Has an A l c between 7.5 - 9.0% based upon point of care testing performed at visit 1.
  • Currently performs self-monitoring blood glucose checks at least 3 times per week.
  • Able to adhere to protocol requirements.

Exclusion Criteria

A subject will be excluded if any of the following criteria are met:

  • Has Type 1 Diabetes or Gestational Diabetes.
  • Is pregnant or planning to become pregnant during the course of the study.
  • Current use OR use in the past 6 months of sulfonylureas.
  • Current use OR use in the past 6 months of insulin
  • History of cardiovascular disease or cerebrovascular disease.
  • Any planned surgery during the course of the study.
  • Current continuous renal replacement therapy.
  • Current oral or injectable steroid use or use within the previous 3 months.
  • Previous or current treatment with deep brain stimulation.
  • Any previous known disease, injury, or surgical intervention involving the brain or central nervous system.
  • Moderate or greater hearing loss.
  • Presence of a cochlear implant.
  • Diagnosed vestibular dysfunction.
  • Eye surgery within the previous three months.
  • Any history of previous ear surgery.
  • Active ear infections or a perforated tympanic membrane.
  • Presence of a serious or unstable medical or psychological condition which, in the opinion of the investigator, would compromise the subject's safety or successful participation in the study.

Sites / Locations

  • UNC Highgate Specialty Center - UNC Diabetes Care Center

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

TNM (thermoneuromodulation device)

Arm Description

A standardized active thermal neuromodulation waveform will be used for all patients. The device is non-invasive and does not use electrical stimulation.

Outcomes

Primary Outcome Measures

Measurement of glycosylated hemoglobin (A1c)
At the end of the 84 day period of device use, the patient's A1c value will be compared with the baseline value to assess any reduction.

Secondary Outcome Measures

Measurement of lipid panel
At the end of the 84 day period of device use, the patient's fasting lipid panel will be taken and compared with the baseline panel to assess any difference in lipid metabolism.
Assessment of quality of life
At the end of the 84 day period of device use, the patient's reports on quality of life measures will be compared with baseline values to assess any improvement.
Assessment of mood
At the end of the 84 day period of device use, the patient's reports on mood measures will be compared with baseline values to assess any improvement.
Assessment of diabetes related self care
At the end of the 84 day period of device use, the patient's reports on diabetes related self care will be compared with baseline values to assess any improvement.
Feasibility and acceptability of the device as an intervention for the diabetes population
At the end of the 84 day period of device use, the patient will be asked to assess the device use experience and note any shortcomings, challenges or difficulties.

Full Information

First Posted
April 30, 2014
Last Updated
September 23, 2015
Sponsor
Scion NeuroStim
search

1. Study Identification

Unique Protocol Identification Number
NCT02130401
Brief Title
Examining the Effects of Neuromodulation on Glucose Metabolism in Type 2 Diabetes
Official Title
Device: Investigational Study to Examine the Effects of Neuromodulation on Glucose Metabolism in Type 2 Diabetes
Study Type
Interventional

2. Study Status

Record Verification Date
September 2015
Overall Recruitment Status
Completed
Study Start Date
June 2014 (undefined)
Primary Completion Date
May 2015 (Actual)
Study Completion Date
June 2015 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Scion NeuroStim

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
This is a pilot study with a single active treatment arm. The study is designed to assess the efficacy of a portable, non-invasive neuromodulation system for the treatment of Type 2 Diabetes. In particular, the primary outcome measure is a reduction in A1c.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Type 2 Diabetes
Keywords
neuromodulation, caloric vestibular stimulation, Type 2 Diabetes

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
6 (Actual)

8. Arms, Groups, and Interventions

Arm Title
TNM (thermoneuromodulation device)
Arm Type
Experimental
Arm Description
A standardized active thermal neuromodulation waveform will be used for all patients. The device is non-invasive and does not use electrical stimulation.
Intervention Type
Device
Intervention Name(s)
TNM (thermoneuromodulation device)
Intervention Description
The device is worn like a music headset and the patient lies on a wedge pillow while the device is active. Each session lasts under 20 minutes.
Primary Outcome Measure Information:
Title
Measurement of glycosylated hemoglobin (A1c)
Description
At the end of the 84 day period of device use, the patient's A1c value will be compared with the baseline value to assess any reduction.
Time Frame
after 84 days of device use
Secondary Outcome Measure Information:
Title
Measurement of lipid panel
Description
At the end of the 84 day period of device use, the patient's fasting lipid panel will be taken and compared with the baseline panel to assess any difference in lipid metabolism.
Time Frame
after 84 days of device use
Title
Assessment of quality of life
Description
At the end of the 84 day period of device use, the patient's reports on quality of life measures will be compared with baseline values to assess any improvement.
Time Frame
after 84 days of device use
Title
Assessment of mood
Description
At the end of the 84 day period of device use, the patient's reports on mood measures will be compared with baseline values to assess any improvement.
Time Frame
after 84 days of device use
Title
Assessment of diabetes related self care
Description
At the end of the 84 day period of device use, the patient's reports on diabetes related self care will be compared with baseline values to assess any improvement.
Time Frame
after 84 days of device use
Title
Feasibility and acceptability of the device as an intervention for the diabetes population
Description
At the end of the 84 day period of device use, the patient will be asked to assess the device use experience and note any shortcomings, challenges or difficulties.
Time Frame
after 84 days of device use

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
70 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria A subject is eligible for the study if all of the following criteria are met: Provide written informed consent prior to enrollment. Is male or female between 18-70 years old. Has been diagnosed with type II diabetes for greater than 12 months. Is currently either using lifestyle modification or taking one or two of the following oral antihyperglycemic agents and has been on stable doses for 90 days prior to screening: metformin DPP-4 inhibitors (sitagliptin, saxagliptin, alogliptin, linaglyptin) Pioglitazone GLP-1 agonist (exenatide, liraglutide, exenatide LAR) SGLT-2 Inhibitors (dapaglifozin, canagliflozin) Has an A l c between 7.5 - 9.0% based upon point of care testing performed at visit 1. Currently performs self-monitoring blood glucose checks at least 3 times per week. Able to adhere to protocol requirements. Exclusion Criteria A subject will be excluded if any of the following criteria are met: Has Type 1 Diabetes or Gestational Diabetes. Is pregnant or planning to become pregnant during the course of the study. Current use OR use in the past 6 months of sulfonylureas. Current use OR use in the past 6 months of insulin History of cardiovascular disease or cerebrovascular disease. Any planned surgery during the course of the study. Current continuous renal replacement therapy. Current oral or injectable steroid use or use within the previous 3 months. Previous or current treatment with deep brain stimulation. Any previous known disease, injury, or surgical intervention involving the brain or central nervous system. Moderate or greater hearing loss. Presence of a cochlear implant. Diagnosed vestibular dysfunction. Eye surgery within the previous three months. Any history of previous ear surgery. Active ear infections or a perforated tympanic membrane. Presence of a serious or unstable medical or psychological condition which, in the opinion of the investigator, would compromise the subject's safety or successful participation in the study.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Lesco Rogers, MD
Organizational Affiliation
Scion NeuroStim
Official's Role
Study Director
Facility Information:
Facility Name
UNC Highgate Specialty Center - UNC Diabetes Care Center
City
Chapel Hill
State/Province
North Carolina
ZIP/Postal Code
27713
Country
United States

12. IPD Sharing Statement

Learn more about this trial

Examining the Effects of Neuromodulation on Glucose Metabolism in Type 2 Diabetes

We'll reach out to this number within 24 hrs